CN107703314B - 一种促肾上腺皮质激素溶液及其应用 - Google Patents
一种促肾上腺皮质激素溶液及其应用 Download PDFInfo
- Publication number
- CN107703314B CN107703314B CN201711129110.8A CN201711129110A CN107703314B CN 107703314 B CN107703314 B CN 107703314B CN 201711129110 A CN201711129110 A CN 201711129110A CN 107703314 B CN107703314 B CN 107703314B
- Authority
- CN
- China
- Prior art keywords
- corticotropin
- solution
- antigen
- trehalose
- casein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5751—Corticotropin releasing factor [CRF] (Urotensin)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2446/00—Magnetic particle immunoreagent carriers
- G01N2446/80—Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种促肾上腺皮质激素溶液及其应用。该溶液含有促肾上腺皮质激素抗原、2‑吗啉乙磺酸、NaCl、海藻糖、酪蛋白、4‑氨基安替比林、水。本发明提供了所述促肾上腺皮质激素溶液的制备方法及其应用。该溶液制备方法简单,节约成本,工艺流程可操控,成品具有良好的稳定性,37℃保持7‑14天,效价保留率仍大于85%,在2~8℃存放12个月后,效价保留率大于90%,可作为促肾上腺皮质激素的校准品或质控品,用于体外定量检测人血浆中促肾上腺皮质激素,具有良好的临床应用前景。
Description
技术领域
本发明涉及体外诊断试剂校准品或质控品,特别是涉及一种制备方法简单、效价稳定的液态促肾上腺皮质激素校准品或质控品及其应用。
背景技术
促肾上腺皮质激素(ACTH)是一种由39个氨基酸组成的肽类激素,分子量约为4.5kD。ACTH在垂体中产生,作用于肾上腺皮质,具有促进肾上腺皮质组织增生、皮质激素生成和分泌的作用。在临床上,ACTH检测对于鉴别诊断肾上腺功能减退和分泌亢进很有价值。因此,出现了针对ACTH测定的体外诊断试剂。
针对ACTH测定的体外诊断试剂中需要配备ACTH质控品或校准品,然而现有技术中液态的ACTH质控品或校准品稳定性差,不宜长期保存,并且对温度敏感,不利于ACTH体外诊断试剂的产业化生产。因此,目前体外诊断试剂中的促肾上腺皮质激素主要以冻干粉的形式保存,使用时再用适当的溶液溶解。然而ACTH冻干粉的冻干工艺复杂,对工作人员、仪器设备等均要求较高,由于工作人员、仪器设备、复溶等不可控的因素均会增大ACTH质控品或校准品产品的批间、瓶间差异,影响检测结果,也在一定程度上增加了产品的生产成本。因此迫切需要一种制备方法简单、容易操作、成本相对较低且成品稳定性好的液态ACTH质控品和校准品。
发明内容
本发明的目的是克服现有技术的缺陷提供一种稳定性好的促肾上腺皮质激素溶液及其应用。
本发明提供的一种促肾上腺皮质激素溶液,含有促肾上腺皮质激素抗原、2-吗啉乙磺酸、NaCl、海藻糖、酪蛋白、4-氨基安替比林、水。
进一步地,本发明的促肾上腺皮质激素溶液还含有表面活性剂、丙三醇和生物防腐剂。
具体地,本发明的促肾上腺皮质激素溶液含有以下成分:2-吗啉乙磺酸10~100mM,NaCl 0.9%,海藻糖0.5%~2%(m/V),酪蛋白 0.5%~2%(m/V),4-氨基安替比林0.005‰~0.05‰(m/V),表面活性剂 0.05‰~0.5‰(V/V),丙三醇0.05‰~0.5‰(V/V),生物防腐剂 0.5‰~2‰(V/V),促肾上腺皮质激素抗原1~2000pg/ml,pH5.5~6.7。
进一步地,本发明的促肾上腺皮质激素溶液含有以下成分:2- 吗啉乙磺酸10~50mM,NaCl 0.9%,海藻糖0.8%~1.5%(m/V),酪蛋白0.8%~1.5%(m/V),4-氨基安替比林0.01‰~0.04‰(m/V),表面活性剂0.05‰~0.3‰(V/V),丙三醇0.05‰~0.3‰(V/V),生物防腐剂 0.5‰~1‰(V/V),促肾上腺皮质激素抗原5~2000pg/ml,pH5.5~6.7。
优选地,本发明的促肾上腺皮质激素溶液含有以下成分:2-吗啉乙磺酸10~30mM,NaCl 0.9%,海藻糖0.8%~1.2%(m/V),酪蛋白 0.8%~1.2%(m/V),4-氨基安替比林0.01‰~0.03‰(m/V),TX-100 0.08‰~0.2‰(V/V),丙三醇0.08‰~0.2‰(V/V),Proclin300 0.5‰~1‰(V/V),促肾上腺皮质激素抗原5~2000pg/ml,pH5.5~6.7。
更优选地,本发明的促肾上腺皮质激素溶液含有以下成分:2- 吗啉乙磺酸20mM,NaCl 0.9%,海藻糖1%(m/V),酪蛋白1%(m/V), 4-氨基安替比林0.02‰(m/V),TX-1000.1‰(V/V),丙三醇0.1‰(V/V), Proclin300 1‰(V/V),促肾上腺皮质激素抗原5~2000pg/ml, pH5.9~6.1。
本发明提供了制备上述的促肾上腺皮质激素溶液的方法,包括以下步骤:
(1)2-吗啉乙磺酸溶于水,再加入NaCl,完全溶解后,调pH 值至5.4-5.6;
(2)向步骤(1)溶液中依次加入海藻糖、酪蛋白、4-氨基安替比林、表面活性剂、丙三醇、生物防腐剂,之后加NaOH或盐酸调 pH值至5.5-6.7;pH值优选5.9-6.1;
(3)向步骤(2)的溶液中加入促肾上腺皮质激素抗原。
本发明的促肾上腺皮质激素溶液可作为ACTH校准品或质控品。
本发明提供了所述促肾上腺皮质激素溶液在制备促肾上腺功能相关疾病诊断试剂盒中的应用。
含有本发明所述的促肾上腺皮质激素溶液的试剂盒或诊断试剂属于本发明的保护范围。
本发明提供了所述促肾上腺皮质激素溶液在非疾病诊断目的的体外促肾上腺皮质激素定性或定量检测中的应用。
本发明具有以下有益效果:(1)本发明的促肾上腺皮质激素溶液制备方法简单,对工作人员和仪器设备均无苛刻要求,便于操作和配制;克服了现有技术中ACTH冻干粉的冻干工艺复杂,对工作人员、仪器设备等均要求较高的缺点;(2)本发明的促肾上腺皮质激素溶液稳定性好,能够在37℃放置14天,效价保留率>85%,在2~8℃存放12个月后,效价保留率≥90%,符合使用要求;(3)制备成本有效降低;(4)可作为促肾上腺皮质激素的校准品或质控品,用于非疾病诊断目的的促肾上腺皮质激素的体外定量检测,具有良好的临床应用前景。
具体实施方式
以下实施例用于说明本发明,但不用来限制本发明的范围。抗 ACTH单克隆抗体、磁微粒、吖啶酯和发光激发液均购自四川迈克生物新材料技术有限公司,制备后获得包被抗ACTH单克隆抗体的磁微粒、吖啶酯标记的抗ACTH单克隆抗体。
实施例1促肾上腺皮质激素溶液的制备
本发明促肾上腺皮质激素溶液包括以下步骤:
(1)2-吗啉乙磺酸溶于水,再加入NaCl,完全溶解后,加NaOH 或盐酸调pH值至5.4-5.6;
(2)向步骤(1)溶液中依次加入海藻糖、酪蛋白、4-氨基安替比林、表面活性剂、丙三醇、生物防腐剂,之后加NaOH或盐酸调 pH值至5.5-6.7;pH优选5.9-6.1。
(3)向步骤(2)的溶液中加入促肾上腺皮质激素抗原。
具体成分的用量和来源见表1。以纯化水为配液溶剂,前一物料完全溶解后才能投入另一物料。
表1
实施例2促肾上腺皮质激素溶液的性能评价
采用表2中A、B、C、D、E五组不同的配方,进行稳定性试验。其中B组为本发明促肾上腺皮质激素溶液的各组分最佳配比,C组为本发明促肾上腺皮质激素溶液的各组分较高浓度配比,D组为本发明促肾上腺皮质激素溶液的各组分较低浓度配比,E组除未添加4-氨基安替比林外其他组分配比、pH值与B组相同。
表2
A | B | C | D | E | |
磷酸缓冲液 | 20mM | / | / | / | / |
2-吗啉乙磺酸 | / | 20mM | 100mM | 10mM | 20mM |
NaCl | 0.90% | 0.90% | 0.90% | 0.90% | 0.90% |
海藻糖 | 1% | 1% | 2% | 0.50% | 1% |
酪蛋白 | 1% | 1% | 2% | 0.50% | 1% |
4-氨基安替比例 | 0.02‰ | 0.02‰ | 0.05‰ | 0.005‰ | / |
TritonX-100 | 0.1‰ | 0.1‰ | 0.5‰ | 0.05‰ | 0.1‰ |
丙三醇 | 0.1‰ | 0.1‰ | 0.5‰ | 0.05‰ | 0.1‰ |
Proclin300 | 1‰ | 1‰ | 1‰ | 0.5‰ | 1‰ |
促肾上腺皮质激素抗原 | * | * | * | * | * |
pH | 7.4 | 6.0 | 6.7 | 5.5 | 6.0 |
注:表中“/”为未添加;“*”为根据实际需求添加不同用量的ACTH抗原。
1、热稳定性实验:按表2中A、B、C、D、E配置成促肾上腺皮质激素溶液,每组含有两个浓度水平L1(20~40pg/mL)和L2 (800~1200pg/mL),分别经37℃、45℃热破坏7天和14天后,搭配包被有抗ACTH单克隆抗体的磁微粒、吖啶酯标记的抗ACTH单克隆抗和发光激发液,检测发光信号值(本发明实施例2的促肾上腺皮质激素溶液与包被抗ACTH单克隆抗体的磁微粒、吖啶酯标记的抗ACTH 单克隆抗体结合形成双抗体夹心复合物,该夹心复合物可与发光激发液发生化学发光反应,通过光检测系统测量相对发光信号值(RLUs)),每个浓度水平测定3次,把3次测定结果的均值作为该浓度的RLUs检测结果,并计算37℃、45℃条件下与2~8℃的RLUs保留率。(RLUs保留率与试剂效价呈正相关)
表3各组溶液ACTH的浓度
表4 A组(磷酸盐缓冲液对照组)热稳定性结果
表5 B组热稳定性结果
表6 C组热稳定性结果
表7 D组热稳定性结果
表8 E组(对照组:不加4-AAP)热稳定性结果
由以上数据可知,B配方的促肾上腺皮质激素溶液的热稳定性明显优于A配方,可见2-吗啉乙磺酸(MES)对试剂的热稳定性起着关键作用;E配方的促肾上腺皮质激素溶液的热稳定性比A好,弱于B,说明4-氨基安替比林对试剂的热稳定性起着明显的协同作用;根据B、C、D配成的促肾上腺皮质激素溶液在37℃放置14天后,RLUs保留率大于85%,说明所述溶液的热稳定性良好,利于试剂的运输、使用。
2、长期稳定性:根据B配方配成的终浓度为5pg/mL(a)、25pg/mL (b)、50pg/mL(c)、125pg/mL(d)、500pg/mL(e)、1000pg/mL(f)、 2000pg/mL(g)的促肾上腺皮质激素溶液,搭配包被有抗ACTH单克隆抗体的磁微粒、吖啶酯标记的抗ACTH单克隆抗和发光激发液,检测相对发光信号值(RLUs),作出“浓度-RLUs”的标准曲线。按条件 A、B、C、D、E配置成促肾上腺皮质激素溶液,见表3,保存在2℃~8℃条件里,分别在第3、6、9、12个月检测RLUs(取每个浓度水平重复 3次检测结果的均值),通过上述标准曲线计算浓度值。并计算第3、6、 9、12个月的浓度值与配制浓度的百分比,即浓度保留率。(浓度保留率与试剂效价呈正相关)
表9 A组长期稳定性观察
表10 B组长期稳定性观察
表11 C组长期稳定性观察
表12 D组长期稳定性观察
表13 E组长期稳定性观察
由以上数据可知,根据A、B、C、D、E配成的促肾上腺皮质激素溶液在2~8℃的环境下存放12个月,A的长期稳定性效果最差,浓度保留率约65%;B的浓度保留率几乎没有变化,接近100%,长期稳定性效果最佳;C、D的浓度保留率显逐渐缓慢降低的趋势,均≥90%;E的浓度保留率高于A,约80%。
综上所述,本发明的促肾上腺皮质激素溶液,配置简单、成本低廉,具有更好的热稳定性,在2~8℃的环境下可稳定存放12个月,可作为促肾上腺皮质激素的校准品或质控品,具有良好的临床应用前景。
虽然,上文中已经用一般性说明及具体实施方案对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (8)
1.一种促肾上腺皮质激素溶液,其特征在于,含有以下成分:2-吗啉乙磺酸10~100mM,NaCl 0.9%,海藻糖0.5%~2%(m/V),酪蛋白0.5%~2%(m/V),4-氨基安替比林0.005‰~0.05‰(m/V),表面活性剂0.05‰~0.5‰(V/V),丙三醇0.05‰~0.5‰(V/V),生物防腐剂0.5‰~2‰(V/V),促肾上腺皮质激素抗原1~2000pg/ml,pH5.5-6.7。
2.如权利要求1所述的促肾上腺皮质激素溶液,其特征在于,含有以下成分:2-吗啉乙磺酸10~50mM,NaCl 0.9%,海藻糖0.8%~1.5%(m/V),酪蛋白0.8%~1.5%(m/V),4-氨基安替比林0.01‰~0.04‰(m/V),表面活性剂0.05‰~0.3‰(V/V),丙三醇0.05‰~0.3‰(V/V),生物防腐剂0.5‰~1‰(V/V),促肾上腺皮质激素抗原5~2000pg/ml,pH5.5-6.7。
3.如权利要求1-2任一所述的促肾上腺皮质激素溶液,其特征在于,含有以下成分:2-吗啉乙磺酸10~30mM,NaCl 0.9%,海藻糖0.8%~1.2%(m/V),酪蛋白0.8%~1.2%(m/V),4-氨基安替比林0.01‰~0.03‰(m/V),Triton X-100 0.08‰~0.2‰(V/V),丙三醇0.08‰~0.2‰(V/V),Proclin300 0.5‰~1‰(V/V),促肾上腺皮质激素抗原5~2000pg/ml,pH5.5-6.7。
4.如权利要求1-2任一所述的促肾上腺皮质激素溶液,其特征在于,含有以下成分:2-吗啉乙磺酸20mM,NaCl 0.9%,海藻糖1%(m/V),酪蛋白1%(m/V),4-氨基安替比林0.02‰(m/V),TritonX-100 0.1‰(V/V),丙三醇0.1‰(V/V),Proclin300 1‰(V/V),促肾上腺皮质激素抗原5~2000pg/ml,pH5.9-6.1。
5.制备权利要求1-4任一所述的促肾上腺皮质激素溶液的方法,其特征在于,包括以下步骤:
(1)2-吗啉乙磺酸溶于水,再加入NaCl,完全溶解后,调pH值至5.4-5.6;
(2)向步骤(1)溶液中依次加入海藻糖、酪蛋白、4-氨基安替比林、表面活性剂、丙三醇、生物防腐剂,之后加NaOH或盐酸调pH值至5.5-6.7;
(3)向步骤(2)的溶液中加入促肾上腺皮质激素抗原。
6.权利要求1-4任一所述的促肾上腺皮质激素溶液在制备液态ACTH校准品或质控品中的应用。
7.权利要求1-4任一所述的促肾上腺皮质激素溶液在制备促肾上腺功能相关疾病诊断试剂盒中的应用。
8.含有权利要求1-4任一所述的促肾上腺皮质激素溶液的试剂盒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711129110.8A CN107703314B (zh) | 2017-11-15 | 2017-11-15 | 一种促肾上腺皮质激素溶液及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711129110.8A CN107703314B (zh) | 2017-11-15 | 2017-11-15 | 一种促肾上腺皮质激素溶液及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107703314A CN107703314A (zh) | 2018-02-16 |
CN107703314B true CN107703314B (zh) | 2018-11-20 |
Family
ID=61179803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711129110.8A Active CN107703314B (zh) | 2017-11-15 | 2017-11-15 | 一种促肾上腺皮质激素溶液及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107703314B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108548930B (zh) * | 2018-03-30 | 2021-11-09 | 迈克生物股份有限公司 | 促肾上腺皮质激素化学发光检测试剂盒 |
CN108398423B (zh) * | 2018-03-30 | 2021-08-06 | 迈克生物股份有限公司 | 肾素化学发光检测试剂盒 |
CN108508000B (zh) * | 2018-03-30 | 2021-08-06 | 迈克生物股份有限公司 | 乙肝前s1抗原化学发光检测试剂盒 |
CN108508001B (zh) * | 2018-03-30 | 2021-08-06 | 迈克生物股份有限公司 | 化学发光检测试剂盒 |
CN108444988B (zh) * | 2018-03-30 | 2021-08-06 | 迈克生物股份有限公司 | 甲状腺球蛋白化学发光检测试剂盒 |
CN109142715A (zh) * | 2018-07-03 | 2019-01-04 | 江南大学 | 一种新型纳米磁微粒悬浮体系及其配制方法 |
CN112812173B (zh) * | 2019-11-17 | 2022-08-26 | 烟台东诚药业集团股份有限公司 | 一种促肾上腺皮质激素粗品精制的方法 |
CN111896754B (zh) * | 2020-08-04 | 2023-07-18 | 四川沃文特生物技术有限公司 | 一种pct校准品缓冲溶液 |
CN112540171B (zh) * | 2020-12-04 | 2023-12-22 | 郑州标源生物科技有限公司 | 一种促肾上腺皮质激素质控品及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003104486A1 (ja) * | 2002-06-10 | 2003-12-18 | 株式会社シノテスト | トリグリセライドの選択的測定方法 |
EP2108961A1 (en) * | 2008-04-10 | 2009-10-14 | Fujifilm Corporation | Dry analytical element for measurement of high density lipoprotein cholesterol |
CN102998445A (zh) * | 2012-12-12 | 2013-03-27 | 元升生物科技(上海)有限公司 | 一种测定甘胆酸的试剂及制备方法 |
CN106324255A (zh) * | 2016-08-17 | 2017-01-11 | 山东博科生物产业有限公司 | 一种稳定性强的生化用特种蛋白液体复合质控品 |
CN106568976A (zh) * | 2016-11-04 | 2017-04-19 | 江苏福隆生物技术有限公司 | 一种神经元特异性烯醇化酶稳定剂及其制备方法 |
CN107290545A (zh) * | 2017-06-19 | 2017-10-24 | 威海威仕泰医疗科技有限公司 | 一种稳定的β2微球蛋白溶液、其制备方法及应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104198733B (zh) * | 2014-08-13 | 2015-07-15 | 宁波瑞源生物科技有限公司 | 一种稳定的液体脂类校准品 |
CN104965091B (zh) * | 2015-05-22 | 2016-08-24 | 宁波美康生物科技股份有限公司 | 一种唾液酸质控品及其制备方法 |
CN107167539B (zh) * | 2017-06-27 | 2019-07-23 | 中山出入境检验检疫局检验检疫技术中心 | 一种快速筛查鱼肉中多种兽药残留的检测方法 |
-
2017
- 2017-11-15 CN CN201711129110.8A patent/CN107703314B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003104486A1 (ja) * | 2002-06-10 | 2003-12-18 | 株式会社シノテスト | トリグリセライドの選択的測定方法 |
EP2108961A1 (en) * | 2008-04-10 | 2009-10-14 | Fujifilm Corporation | Dry analytical element for measurement of high density lipoprotein cholesterol |
CN102998445A (zh) * | 2012-12-12 | 2013-03-27 | 元升生物科技(上海)有限公司 | 一种测定甘胆酸的试剂及制备方法 |
CN106324255A (zh) * | 2016-08-17 | 2017-01-11 | 山东博科生物产业有限公司 | 一种稳定性强的生化用特种蛋白液体复合质控品 |
CN106568976A (zh) * | 2016-11-04 | 2017-04-19 | 江苏福隆生物技术有限公司 | 一种神经元特异性烯醇化酶稳定剂及其制备方法 |
CN107290545A (zh) * | 2017-06-19 | 2017-10-24 | 威海威仕泰医疗科技有限公司 | 一种稳定的β2微球蛋白溶液、其制备方法及应用 |
Non-Patent Citations (2)
Title |
---|
Operational stability of immobilised horseradish peroxidase in mini-packed bed bioreactors;A.M. Azevedo et al.,;《Journal of Molecular Catalysis B: Enzymatic》;20041231;第28卷;全文 * |
生化液体质控品与冻干质控品的应用比较;罗浔阳 等;《临床检验杂志》;20041231;第22卷(第5期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN107703314A (zh) | 2018-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107703314B (zh) | 一种促肾上腺皮质激素溶液及其应用 | |
Callegari et al. | A MICOS–TIM22 association promotes carrier import into human mitochondria | |
Bai et al. | Associations of chemo-and radio-resistant phenotypes with the gap junction, adhesion and extracellular matrix in a three-dimensional culture model of soft sarcoma | |
Paroder et al. | Na+/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: molecular characterization of SMCT | |
Kim et al. | Activated AKT pathway promotes establishment of endometriosis | |
Yang et al. | Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts | |
ES2947826T3 (es) | Célula endotelial corneal funcional humana y aplicación de la misma | |
Kuhn et al. | Secretome analysis of cardiomyocytes identifies PCSK6 (proprotein convertase subtilisin/kexin type 6) as a novel player in cardiac remodeling after myocardial infarction | |
Ortiz-Masia et al. | Induction of CD36 and thrombospondin-1 in macrophages by hypoxia-inducible factor 1 and its relevance in the inflammatory process | |
Zhu et al. | Human umbilical cord blood mesenchymal stem cell transplantation suppresses inflammatory responses and neuronal apoptosis during early stage of focal cerebral ischemia in rabbits | |
Liu et al. | MicroRNA-122 influences the development of sperm abnormalities from human induced pluripotent stem cells by regulating TNP2 expression | |
Zhang et al. | Regulation of transplanted mesenchymal stem cells by the lung progenitor niche in rats with chronic obstructive pulmonary disease | |
Ma et al. | Testosterone-dependent miR-26a-5p and let-7g-5p act as signaling mediators to regulate sperm apoptosis via targeting PTEN and PMAIP1 | |
Flemming et al. | miRNA-and cytokine-associated extracellular vesicles mediate squamous cell carcinomas | |
Jameel et al. | Long-term functional improvement and gene expression changes after bone marrow-derived multipotent progenitor cell transplantation in myocardial infarction | |
Moustogiannis et al. | The effects of muscle cell aging on myogenesis | |
Li et al. | Role of exosomes induced by remote ischemic preconditioning in neuroprotection against cerebral ischemia | |
Ricci et al. | Homeodomain‐interacting protein kinase2 in human idiopathic pulmonary fibrosis | |
Caccuri et al. | SARS-CoV-2 infection remodels the phenotype and promotes angiogenesis of primary human lung endothelial cells | |
Sun et al. | Comparative proteomic analysis of follicular fluids from normal and cystic follicles in sows | |
Gonçalves et al. | p27 kip1 overexpression regulates VEGF expression, cell proliferation and apoptosis in cell culture from eutopic endometrium of women with endometriosis | |
van der Spek et al. | The thyroid hormone inactivating type 3 deiodinase is essential for optimal neutrophil function: observations from three species | |
Hanics et al. | Secretagogin-dependent matrix metalloprotease-2 release from neurons regulates neuroblast migration | |
Murphy et al. | Human amnion epithelial cells induced to express functional cystic fibrosis transmembrane conductance regulator | |
Penheiter et al. | Transcriptomic and immunohistochemical profiling of SLC6A14 in pancreatic ductal adenocarcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |